Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations

• Published in: British journal of cancer 1999-02, Vol.79 (5), p.787-792
• Main Authors: Boland, I, Vassal, G, Morizet, J, Terrier-Lacombe, M-J, Valteau-Couanet, D, Kalifa, C, Hartmann, O, Gouyette, A
• Format: Article
• Language: English
• Subjects: Administration, Oral; Animals; Antineoplastic agents; Biological and medical sciences; Biological Availability; Biomedical and Life Sciences; Biomedicine; Brain Neoplasms - blood; Brain Neoplasms - drug therapy; Busulfan - administration & dosage; Busulfan - blood; Busulfan - pharmacokinetics; Busulfan - therapeutic use; Cancer Research; Carboxymethylcellulose Sodium; Chemotherapy; Dimethyl Sulfoxide; Drug Resistance; Epidemiology; Female; Humans; Injections, Intraperitoneal; Medical sciences; Medulloblastoma - blood; Medulloblastoma - drug therapy; Mice; Mice, Nude; Molecular Medicine; Neuroblastoma - blood; Neuroblastoma - drug therapy; Neuroectodermal Tumors, Primitive - blood; Neuroectodermal Tumors, Primitive - drug therapy; Oncology; Pharmacology. Drug treatments; Regular; regular-article; Solubility; Transplantation, Heterologous; Tumor Cells, Cultured
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/sj.bjc.6690126

Summary High-dose busulphan-containing chemotherapy regimens have shown high response rates in children with relapsed or refractory neuroblastoma, Ewing’s sarcoma and medulloblastoma. However, the anti-tumour activity of busulfan as a single agent remains to be defined, and this was evaluated in athymic mice bearing advanced stage subcutaneous paediatric solid tumour xenografts. Because busulphan is highly insoluble in water, the use of several vehicles for enteral and parenteral administration was first investigated in terms of pharmacokinetics and toxicity. The highest bioavailability was obtained with busulphan in DMSO administered i.p. When busulphan was suspended in carboxymethylcellulose and given orally or i.p., the bioavailability was poor. Then, in the therapeutic experiments, busulphan in DMSO was administered i.p. on days 0 and 4. At the maximum tolerated total dose (50 mg kg –1 ), busulphan induced a significant tumour growth delay, ranging from 12 to 34 days in the three neuroblastomas evaluated and in one out of three medulloblastomas. At a dose level above the maximum tolerated dose, busulphan induced complete and partial tumour regressions. Busulphan was inactive in a peripheral primitive neuroectodermal tumour (PNET) xenograft. When busulphan pharmacokinetics in mice and humans were considered, the estimated systemic exposure at the therapeutically active dose in mice (113 μg h ml –1 ) was close to the mean total systemic exposure in children receiving high-dose busulphan (102.4 μg h ml –1 ). In conclusion, busulphan displayed a significant anti-tumour activity in neuroblastoma and medulloblastoma xenografts at plasma drug concentrations which can be achieved clinically in children receiving high-dose busulphan-containing regimens.